Wockhardt expects to resolve most FDA concerns within the year – FiercePharma Manufacturing
0
Wockhardt has been in a world of hurt since the FDA last year banned two of the plants that made drugs for the U.S. market. But the Indian drugmaker has said that with the help of outside consultants it can get most of its problems with the FDA resolved within the year, and that has the M&A handicappers suggesting it is prime takeover target.
“If you’re confident in your capabilities that you can turn around and manage the U.S. business in a high-quality manner, you can buy some of those assets at a relatively cheap price,” Nitin Agarwal, a Mumbai-based analyst at IDFC, tells Bloomberg.
While Wockhardt officials insist it has no interest in selling, that has not stopped analysts from playing matchmaker, especially since execs at India’s Lupin acknowledged recently that they analyzed whether buying Wockhardt would make sense. The analysts are suggesting some of the usual suspects: Teva Pharmaceutical Industries ($TEVA), Actavis ($ACT) and Mylan ($MYL), Bloomberg reports.
Read more – FiercePharma Manufacturing